Slingshot members are tracking this event:

Regeneron (REGN) Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details  The combination therapy did not demonstrate an improvement in best corrected visual acuity (BCVA) compared to intravitreal aflibercept injection monotherapy at 12 weeks, the primary endpoint of the study. At 12 weeks, patients in both combination aflibercept/rinucumab groups showed a 5.8 letter improvement in BCVA. Patients treated with aflibercept alone showed a 7.5 letter improvement in BCVA. 
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 30, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Aflibercept, Rinucumab, Anti-pdgfr-beta, Neovascular Age-related Macular Degeneration